Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05664334 | Safety and Immunogenicity of IVX-A12 in Healthy Older Adults | PHASE1 | COMPLETED | 140 | — | — | Sep 1, 2022 | Jan 1, 2024 | Mar 4, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| IVX-121 | BIOLOGICAL | 75 mcg of IVX-121 without MF59® |
| IVX-241 | BIOLOGICAL | 75 mcg of IVX-241 without MF59® |
| Placebo | BIOLOGICAL | Diluent |
| MF59® | OTHER | MF59® as an adjuvant |